Advertisement

ADVERTISEMENT

Jordan Kadish

News
Bridging and Salvage Radiotherapy Significantly Improved In-Field Control Among Patients With R/R MCL
11/06/2023
The use of radiotherapy as a bridging and salvage approach significantly improved in-field control outcomes and safety in the peri-CAR T setting among patients with R/R mantle cell lymphoma.
The use of radiotherapy as a bridging and salvage approach significantly improved in-field control outcomes and safety in the peri-CAR T setting among patients with R/R mantle cell lymphoma.
The use of radiotherapy as a...
11/06/2023
Oncology
News
Pembrolizumab Plus Vorinostat Shows Tolerable Safety and Promising Responses for Patients With PD-1 Blockade Refractory Classical Hodgkin Lymphoma
01/17/2024
A combination of pembrolizumab plus vorinostat exhibited tolerable safety and promising overall response rates among patients with classical Hodgkin lymphoma refractory to PD-1 blockade, according to a phase 1 dose expansion study.
A combination of pembrolizumab plus vorinostat exhibited tolerable safety and promising overall response rates among patients with classical Hodgkin lymphoma refractory to PD-1 blockade, according to a phase 1 dose expansion study.
A combination of pembrolizumab...
01/17/2024
Oncology
News
Filgrastim Biosimilar Demonstrated Comparable Efficacy to Originator Filgrastim in Peripheral Blood CD34+ Stem Cell Mobilization Among Patients With Hematologic Malignancies
05/25/2023
A filgrastim biosimilar had similar efficacy in peripheral blood CD34+ stem cell mobilization for both autologous and allogeneic stem cell transplantation compared to the referent among patients with hematologic malignancies.
A filgrastim biosimilar had similar efficacy in peripheral blood CD34+ stem cell mobilization for both autologous and allogeneic stem cell transplantation compared to the referent among patients with hematologic malignancies.
A filgrastim biosimilar had...
05/25/2023
Oncology
News
Intramuscular JZP458 for Patients With AML With Hypersensitivity to E. Coli-Derived Asparaginases
04/14/2023
According to findings of a phase 2/3 trial, intramuscular JZP458 yielded safe and effective results among patients with ALL or lymphoblastic leukemia with hypersensitivity/silent inactivation to asparaginases.
According to findings of a phase 2/3 trial, intramuscular JZP458 yielded safe and effective results among patients with ALL or lymphoblastic leukemia with hypersensitivity/silent inactivation to asparaginases.
According to findings of a phase...
04/14/2023
Oncology
News
BTK Inhibitor Ibrutinib Plus Venetoclax Improved PFS vs Chlorambucil and Obinutuzumab Regimen Among Older Patients With Previously Untreated CLL
09/01/2023
BTK inhibitor ibrutinib plus BCL-2 inhibitor venetoclax improved progression-free survival among older or comorbid patients with previously untreated chronic lymphocytic leukemia vs treatment with chlorambucil and obinutuzumab.
BTK inhibitor ibrutinib plus BCL-2 inhibitor venetoclax improved progression-free survival among older or comorbid patients with previously untreated chronic lymphocytic leukemia vs treatment with chlorambucil and obinutuzumab.
BTK inhibitor ibrutinib plus...
09/01/2023
Oncology
News
FDA Raises Concern About Serious Risk of Secondary T-Cell Malignancy Among Patients Treated With CAR T-Cell Therapies
12/05/2023
On November 28, 2023, the FDA reported on the serious risks of secondary T-cell malignancies developing among patients treated with approved BCMA- or CD19 genetically modified autologous CAR T-cell immunotherapies.
On November 28, 2023, the FDA reported on the serious risks of secondary T-cell malignancies developing among patients treated with approved BCMA- or CD19 genetically modified autologous CAR T-cell immunotherapies.
On November 28, 2023, the FDA...
12/05/2023
Oncology
News
Fractionated Gemtuzumab Ozogamicin Results in Improved Survival and MRD Reduction Among Older Patients With AML
02/08/2024
A fractionated schedule of gemtuzumab ozogamicin resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab ozogamicin.
A fractionated schedule of gemtuzumab ozogamicin resulted in improved overall survival and a greater reduction in measurable residual disease among older patients with acute myeloid leukemia, compared to single-dose gemtuzumab ozogamicin.
A fractionated schedule of...
02/08/2024
Oncology
News
Venetoclax With FLAG-IDA Yielded High Remission and Transition to Transplant Rates in Patients With R/R Acute Myeloid Leukemia
02/09/2023
An updated phase 2b study found that the combination of venetoclax and FLAG-IDA therapy for patients with R/R AML resulted in deep remission and a high rate of transition to transplant.
An updated phase 2b study found that the combination of venetoclax and FLAG-IDA therapy for patients with R/R AML resulted in deep remission and a high rate of transition to transplant.
An updated phase 2b study found...
02/09/2023
Oncology
Conference Coverage
R-CHP Plus Polatuzumab Vedotin Regimen Improved Progression-Free Survival Compared to R-CHOP Among Elderly Patients With DLBCL
06/02/2023
Findings from a phase 3 trial indicated that a polatuzumab vedotin and R-CHP regimen significantly improved the progression-free survival among elderly patients with diffuse large B-cell lymphoma compared to an R-CHOP regimen.
Findings from a phase 3 trial indicated that a polatuzumab vedotin and R-CHP regimen significantly improved the progression-free survival among elderly patients with diffuse large B-cell lymphoma compared to an R-CHOP regimen.
Findings from a phase 3 trial...
06/02/2023
Oncology
News
Lenalidomide, Rituximab, and Venetoclax Combination Demonstrates Efficacy, Safety for Patients With Untreated MCL
07/18/2023
The combination of lenalidomide, rituximab, and venetoclax yielded high efficacy and safety among patients with untreated mantle cell lymphoma.
The combination of lenalidomide, rituximab, and venetoclax yielded high efficacy and safety among patients with untreated mantle cell lymphoma.
The combination of lenalidomide,...
07/18/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD logo
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use